PATENT CLAIM ANALYSIS

Application Number: 15893102
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["424", "139100"]

Abstract:
Provided are methods for clinical treatment of hematological malignancies, such as relapsed or refractory chronic lymphocytic leukemia or lymphoma using an anti-LAG-3 antibody. Particular malignancies include, e.g., chronic lymphocytic leulcemia (CLL), Hodgkin lymphoma (HL), or non-Hodgkin lymphoma (NHL).

Claim (Index 5):
The method of  claim 1 , wherein the treatment produces at least one therapeutic effect chosen from a reduction in the number of malignant cells, inhibition of malignant cell infiltration, inhibition of malignant cell metastasis, prevention occurrence of malignant cells, and reduction of one or more of the symptoms associated with the malignancy.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 88.0
- Lexical Diversity: 1.45714
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15021102', '15032919', '14437029', '15703126', '15166114']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7868269830247792
- 35 USC 102 Novelty (BERT): 0.5751270173114673
- Combined Prediction Score: 0.765656986453448
- Mean Citation Score: 420.279788
- Max Citation Score: 491.10278
- Similarity Product: 393.2866811716676

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test